Literature DB >> 2446069

Antihypertensive mode of action of ketanserin.

J I Robertson1, D J Stott, S G Ball.   

Abstract

The mechanism of blood pressure reduction by ketanserin in hypertensive patients is still not fully understood. It can occur in the absence of evident alpha 1-adrenergic blockade. However, particularly with prolonged therapy, features of alpha 1 blockade appear. There are both similarities and differences between the pattern of effects caused by ketanserin and prazosin. A central mode of action of ketanserin contributing to the blood pressure reduction is not excluded. It appears unlikely, however, that inhibition of aldosterone secretion makes a substantial contribution to the antihypertensive effect of ketanserin in humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446069

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Ageing, serotonin and ketanserin.

Authors:  A Breckenridge
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.

Authors:  Y Ito; M Isaka; H Noda; Y Sato; T Fujita
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  The effects of the 5 HT2 antagonist ketanserin in adult atopic asthma.

Authors:  D J Stott; J A Roberts; N C Thomson; S G Ball
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Effect of ketanserin, a selective antiserotoninergic drug, on human anal canal pressure.

Authors:  M Neri; L Marzio; C De Angelis; O Pieramico; A Mezzetti; F Cuccurullo
Journal:  Int J Colorectal Dis       Date:  1988-11       Impact factor: 2.571

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.